<DOC>
	<DOCNO>NCT00211926</DOCNO>
	<brief_summary>S. aureus common pathogen involve prosthetic joint infection . StaphVAXÂ® vaccine prevent infection , conjugate purify capsular polysaccharide S. aureus carrier protein . It currently evaluate future licensing . This study aim demonstrate safety immunogenicity single dose StaphVAX patient candidate knee hip arthroplasty .</brief_summary>
	<brief_title>StaphVAX Immunogenicity Orthopedic Implant Patients</brief_title>
	<detailed_description />
	<mesh_term>Staphylococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>age 18 year old candidate knee hip replacement expectation protocol compliance negative pregnancy test , appropriate know S. aureus infection prior 3 month infection prior 2 week Known HIV infection immunomodulatory drug Malignancy ( basal cell squamous cell carcinoma , carcinoma situ cervix , early stage prostate cancer ) Hypersensitivity component StaphVAX</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>vaccine</keyword>
	<keyword>Staphylococcus aureus vaccine</keyword>
</DOC>